RVMD
Revolution Medicines Inc - Ordinary Shares
$44.41
+$0.87(+2.00%)
10
Overall
--
Value
10
Tech
--
Quality
Market Cap
$8.14B
Volume
1.77M
52W Range
$29.17 - $62.40
Target Price
$75.41
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $43.0M | $29.4M | $35.4M | $11.6M | $561.0K | ||
| Total Revenue | $43.0M | $29.4M | $35.4M | $11.6M | $561.0K | ||
| GROSS PROFIT | |||||||
| Gross Profit | $43.0M | $29.4M | $35.4M | $11.6M | $561.0K | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $153.7M | $217.4M | $293.7M | $498.8M | $689.5M | ||
| Research & Development | $132.3M | $186.9M | $253.1M | $423.1M | $592.2M | ||
| Research Expense | $132.3M | $186.9M | $253.1M | $423.1M | $592.2M | ||
| Selling, General & Administrative | $21.4M | $30.4M | $40.6M | $75.6M | $97.3M | ||
| General & Administrative Expenses | $21.4M | $30.4M | $40.6M | $75.6M | $97.3M | ||
| Salaries & Wages | -- | -- | $31.2M | $61.8M | $79.2M | ||
| Depreciation & Amortization | $2.6M | $3.1M | $4.0M | $5.0M | $6.2M | ||
| Depreciation & Amortization | $2.6M | $3.1M | $4.0M | $5.0M | $6.2M | ||
| Amortization | $60.9M | $59.9M | $58.8M | $57.7M | $56.7M | ||
| Other Operating Expenses | $-1.2M | $-1.6M | $-2.5M | $-28.6M | $-11.6M | ||
| OPERATING INCOME | |||||||
| Operating income | $-110.7M | $-188.0M | $-258.3M | $-487.2M | $-689.5M | ||
| EBITDA | $-101.9M | $-179.7M | $-239.5M | $-435.6M | $-595.6M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $71.0K | $12.0K | -- | $303.0K | -- | ||
| Intinc | $2.2M | $929.0K | $9.2M | $47.5M | $86.9M | ||
| Net Non-Operating Interest Income/Expense | $2.2M | $917.0K | $9.2M | $47.5M | $86.9M | ||
| Other Income/Expense | -- | -- | -- | $303.0K | $2.5M | ||
| Other Special Charges | -- | -- | -- | $-303.0K | $-2.5M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-108.5M | $-187.1M | $-249.1M | $-439.9M | $-600.8M | ||
| Pre-Tax Income | $-108.5M | $-187.1M | $-249.1M | $-439.9M | $-600.8M | ||
| INCOME TAX | |||||||
| Tax Provision | $-371.0K | -- | $-420.0K | $-3.5M | $-753.0K | ||
| NET INCOME | |||||||
| Net Income | $-108.2M | $-187.1M | $-248.7M | $-436.4M | $-600.1M | ||
| Net Income (Continuing Operations) | $-108.2M | $-187.1M | $-248.7M | $-436.4M | $-600.1M | ||
| Net Income (Discontinued Operations) | $-108.2M | $-187.1M | $-248.7M | $-436.4M | $-600.1M | ||
| Net Income (Common Stockholders) | $-110.4M | $-187.1M | $-248.7M | $-436.4M | $-600.1M | ||
| Normalized Income | -- | -- | -- | -- | $-1.7B | ||
| TOTALS | |||||||
| Total Expenses | $153.7M | $217.4M | $293.7M | $498.8M | $689.5M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $54.9M | $72.8M | $80.6M | $113.1M | $167.7M | ||
| Average Shares Outstanding (Diluted) | $54.9M | -- | $80.6M | $113.1M | $167.7M | ||
| Shares Outstanding | $73.4M | $74.2M | $90.5M | $164.7M | $185.9M | ||
| Basic EPS | $-2.01 | $-2.57 | $-3.08 | $-3.86 | $-3.58 | ||
| Basic EPS (Continuing Operations) | $-2.01 | $-2.57 | $-3.08 | $-3.86 | $-3.58 | ||
| Diluted EPS | $-2.01 | $-2.57 | $-3.08 | $-3.86 | $-3.58 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.08 | $-3.86 | $-3.58 | ||
| OTHER METRICS | |||||||
| Accrued Preferred Stock Dividends | $2.2M | -- | -- | -- | -- | ||
| Other Gand A | $21.4M | $30.4M | $40.6M | $75.6M | $97.3M | ||
| Otherunder Preferred Stock Dividend | $2.2M | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $2.2M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RVMD | $44.41 | +2.0% | 1.77M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Revolution Medicines Inc - Ordinary Shares Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW